Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	865.78	720.13	363.64	266.72	51.17	7.78
Revenue Growth (YoY)	134.82%	98.03%	36.34%	421.20%	557.93%	11.87%
Cost of Revenue	32.02	-94.92	-44.26	44.4	-12.14	-3.52
Gross Profit	770.87	625.22	319.38	222.32	39.04	4.26
Selling, General & Admin	-286.93	457.87	291.14	-264.41	221.23	160.18
Research & Development	132.09	-303.62	-307	413.45	-379.62	-295.87
Total Operating Expenses	-154.84	154.25	-15.86	149.04	-158.4	-135.69
Operating Income	-7.25	-136.27	-278.76	-455.54	-561.81	-451.79
Interest Income	69.15	130.31	5.55	25.46	34.48	71.76
Interest Expense	-163.13	206.69	100.03	-44.07	50.49	3.91
Total Non-Operating Income (Expense)	-93.98	336.99	105.58	-18.6	84.97	75.67
Pretax Income	-167.26	-212.65	-373.24	-474.14	-577.82	-383.94
Provision for Income Taxes	-663.19	15.38	4.84	7.3	5.38	-0.37
Net Income	495.93	-228.03	-378.08	-481.45	-583.19	-383.58
Net Income to Common	495.93	-228.03	-378.08	-481.45	-583.19	-383.58
Shares Outstanding (Basic)	61	61	58	56	56	55
Shares Outstanding (Diluted)	63	61	58	56	56	55
Shares Change (YoY)	5.14%	4.69%	2.85%	0.38%	2.37%	8.21%
EPS (Basic)	8.01	-3.76	-6.53	-8.55	-10.40	-7.00
EPS (Diluted)	7.38	-3.76	-6.53	-8.55	-10.40	-7.00
Shares Outstanding	62.11	61.98	59.84	56.56	55.94	54.77
Free Cash Flow	60.49	53.9	-306.2	-467.36	-495.7	-441.35
Free Cash Flow Growth	12.23%	-	-	-	-	-
Free Cash Flow Per Share	0.97	0.89	-5.29	-8.30	-8.84	-8.06
Gross Margin	89.04%	86.82%	87.83%	83.36%	76.28%	54.71%
Operating Margin	-0.84%	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Profit Margin	57.28%	-31.67%	-103.97%	-180.51%	-1139.63%	-4931.56%
FCF Margin	6.99%	7.48%	-84.20%	-175.23%	-968.65%	-5674.38%
EBITDA	10.24	-118.58	-261.05	-436.63	-543.86	-436.4
EBITDA Margin	1.18%	-16.47%	-71.79%	-163.70%	-1062.76%	-5610.71%
EBIT	-7.25	-136.27	-278.76	-455.54	-561.81	-451.79
EBIT Margin	-0.84%	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Effective Tax Rate	396.50%	-7.23%	-1.30%	-1.54%	-0.93%	0.10%

SEC Filings: 10-K · 10-Q